瘤免疫微环境与早期肺腺癌的复发有关
Hiroaki Kanemura1, Toshihide Yokoyama2, Ryu Nakajima3
1Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
JTO clinical and research reports
|April 23, 2024
概括
像PD-L1,CD8T细胞透和TP53突变这样的生物标志物可以识别早期非小细胞肺癌 (NSCLC) 患者在化疗后复发的风险. 这有助于为改善结果量身定制辅助治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 免疫检查点抑制剂已被批准用于外科手术期间的早期非小细胞肺癌 (NSCLC).
- 鉴定可能在辅助化疗后复发或受益于免疫治疗的患者仍然是一个挑战.
研究的目的:
- 评估癌症干细胞标记物 (CD44,CD133),PD-L1表达,CD8+瘤透淋巴细胞和瘤突变负担.
- 在接受辅助化疗的切除II-IIIA阶段NSCLC患者中确定预测无复发生存 (RFS) 的生物标志物.
主要方法:
- 来自WJOG4107试验 (WJOG12219LTR研究) 档案样本的生物标志物分析.
- 根据PD-L1和CD8+TIL密度分类为炎症或非炎症的瘤.
- 卡普兰-梅尔分析评估了生物标志物和RFS之间的关联.
主要成果:
- 炎症性腺癌与非炎症性腺癌相比,呈现较长RFS的趋势 (中位数未达到与23.7个月).
- 在炎症状态和RFS之间发现了显著的关联 (log-rank p=0.02).
- 没有TP53突变的炎症瘤表现出最长的RFS.
结论:
- PD-L1表达,CD8+ T细胞透和TP53突变状态是潜在的生物标志物.
- 这些生物标志物可能有助于识别在辅助化疗后复发风险的早期NSCLC患者.
相关概念视频
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520